Katherine Stueland
CIK: 0001689575
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
GeneDx Holdings Corp.
Discretionary Trading P&L
Holdings
Transaction History (140 total)
- Sep 16, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct3K shares at avg. $99.00$301K - Sep 16, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct4.1K shares at avg. $98.27$407K - Sep 16, 2026WGS
GeneDx Holdings Corp.
Exercise(M)Direct18.8K shares- - Sep 16, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct1.6K shares at avg. $94.26$155K - Sep 16, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct148 shares at avg. $95.41$14K - Sep 16, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct1.5K shares at avg. $96.90$148K - Sep 9, 2026WGS
GeneDx Holdings Corp.
Exercise(M)Direct6.5K shares- - Sep 9, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct3.7K shares at avg. $84.22$311K - Jun 16, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct2.1K shares at avg. $59.75$128K - Jun 16, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct5.9K shares at avg. $60.83$361K - Jun 16, 2026WGS
GeneDx Holdings Corp.
Exercise(M)Direct18.8K shares- - Jun 16, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct2.4K shares at avg. $61.50$149K - Jun 9, 2026WGS
GeneDx Holdings Corp.
Exercise(M)Direct6.5K shares- - Jun 9, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct3.6K shares at avg. $53.77$196K - Apr 29, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct2.2K shares at avg. $65.20$140K - Apr 29, 2026WGS
GeneDx Holdings Corp.
Exercise(M)Direct3.9K shares- - Apr 29, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct18 shares at avg. $64.12$1K - Mar 26, 2026WGS
GeneDx Holdings Corp.
Exercise(M)Direct80K shares- - Mar 26, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct5.1K shares at avg. $62.33$319K - Mar 26, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct13.4K shares at avg. $63.28$849K - Mar 26, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct5.3K shares at avg. $64.60$342K - Mar 26, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct9.9K shares at avg. $65.21$645K - Mar 26, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct13.2K shares at avg. $61.29$811K - Mar 16, 2026WGS
GeneDx Holdings Corp.
Exercise(M)Direct18.8K shares- - Mar 16, 2026WGS
GeneDx Holdings Corp.
Sale(S)Direct7.2K shares at avg. $76.35$548K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 16, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 3,039 | $99.00 | $300,846 | Direct |
| Sep 16, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 4,141 | $98.27 | $406,936 | Direct |
| Sep 16, 2026 | WGS GeneDx Holdings Corp. | Exercise(M) | 18,750 | - | $0 | Direct |
| Sep 16, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 1,648 | $94.26 | $155,337 | Direct |
| Sep 16, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 148 | $95.41 | $14,120 | Direct |
| Sep 16, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 1,525 | $96.90 | $147,774 | Direct |
| Sep 9, 2026 | WGS GeneDx Holdings Corp. | Exercise(M) | 6,547 | - | $0 | Direct |
| Sep 9, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 3,692 | $84.22 | $310,932 | Direct |
| Jun 16, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 2,140 | $59.75 | $127,874 | Direct |
| Jun 16, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 5,932 | $60.83 | $360,838 | Direct |
| Jun 16, 2026 | WGS GeneDx Holdings Corp. | Exercise(M) | 18,750 | - | $0 | Direct |
| Jun 16, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 2,429 | $61.50 | $149,392 | Direct |
| Jun 9, 2026 | WGS GeneDx Holdings Corp. | Exercise(M) | 6,546 | - | $0 | Direct |
| Jun 9, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 3,639 | $53.77 | $195,669 | Direct |
| Apr 29, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 2,154 | $65.20 | $140,441 | Direct |
| Apr 29, 2026 | WGS GeneDx Holdings Corp. | Exercise(M) | 3,874 | - | $0 | Direct |
| Apr 29, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 18 | $64.12 | $1,154 | Direct |
| Mar 26, 2026 | WGS GeneDx Holdings Corp. | Exercise(M) | 80,000 | - | $0 | Direct |
| Mar 26, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 5,117 | $62.33 | $318,952 | Direct |
| Mar 26, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 13,412 | $63.28 | $848,699 | Direct |
| Mar 26, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 5,292 | $64.60 | $341,859 | Direct |
| Mar 26, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 9,883 | $65.21 | $644,513 | Direct |
| Mar 26, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 13,229 | $61.29 | $810,817 | Direct |
| Mar 16, 2026 | WGS GeneDx Holdings Corp. | Exercise(M) | 18,750 | - | $0 | Direct |
| Mar 16, 2026 | WGS GeneDx Holdings Corp. | Sale(S) | 7,178 | $76.35 | $548,035 | Direct |
1-25 of 140 transactions
About Stueland Katherine
Stueland Katherine (SEC CIK 0001689575) files insider reports with the SEC as CHIEF EXECUTIVE OFFICER of GeneDx Holdings Corp. (WGS).
Signal8 holds 36 ownership filings by Stueland Katherine, all Form 4s, filed between Sep 11, 2024 and Sep 18, 2026. Those filings report 140 transactions, from Mar 26, 2024 to Sep 16, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Stueland Katherine's filings is in STAMFORD, CT.
Recent filings by Stueland Katherine
- Sep 16, 2026: Open-market sales of WGS shares (2 lines, Form 4, code S).
- Sep 16, 2026: Option exercise of WGS shares (Form 4, code M).
- Sep 16, 2026: Open-market sales of WGS shares (3 lines, Form 4, code S).
- Sep 9, 2026: Option exercise of WGS shares (Form 4, code M).
- Sep 9, 2026: Open-market sale of WGS shares (Form 4, code S).
Other insiders filing for GeneDx Holdings Corp. (WGS)
- Feeley Kevin, CHIEF FINANCIAL OFFICER
- Fuchs Thomas, Director
- GARDNER MARK A, President
- Ryan Jason, Director
- RUCH JOSHUA, Director
- PFENNIGER RICHARD C JR, Director